Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone
Conditions
Brief summary
In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term (2x 40 mg) systemic methylprednisolone was administered.
Interventions
BEHAVIORALsystemic methylprednisolone
short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone
Sponsors
Biruni University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 105 Years
Healthy volunteers
No
Inclusion criteria
* Between June 1, 2020 and February 1, 2021, hospitalized in the General intensive care unit of Biruni University Medical Faculty Hospital with the diagnosis of COVID 19; * patients over 18 years of age; (for the diagnosis of COVID 19; Identification of SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) in nasopharyngeal swab or sputum samples and Abnormal lung computed tomography finding (CT) scan finding with \<90% oxygen saturation at rest (bilateral, subpleural, peripheral ground glass opacities)
Exclusion criteria
* Patients with a diagnosis of steroid allergy or developing during treatment; * pregnant or lactating women; * Patients with active malignancy; * Patients taking any immunosuppressive agent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| C Reaktif Protein | 15 DAYS | level of C Reaktif Protein |
Countries
Turkey (Türkiye)
Contacts
Primary Contactilke kupeli
Outcome results
None listed